Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Conditions
Brief summary
This study is conducted in Asia. The aim of this observational study is to evaluate the safety and tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the treatment of Filipino patients with Type 1 and Type 2 Diabetes Mellitus.
Interventions
DRUGinsulin detemir
Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
0 Years to 6 Years
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with Type 1 or Type 2 Diabetes Mellitus. * Newly diagnosed insulin naive patients * Patients currently on human insulin or on basal insulin * Patients prescribed with Levemir™ FlexPen™ (Insulin Detemir) therapy * Usage should be in accordance with the current prescribing information (See attached prescribing information)
Exclusion criteria
* Previous history of hypersensitivity to Insulin Detemir (Levemir™) and its excipients (See attached prescribing information) * Contraindications and warnings specified in the current prescribing information (See attached prescribing information) * Pregnant women, those planning to become pregnant, or women who are breastfeeding * Patients who are already on human premix or premix analogue (unless they are going to be shifted to basal-bolus therapy) * Children below 6 years old
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety profile of Insulin Detemir among Filipino patients | 3 months follow-up visit |
Countries
Philippines
Outcome results
None listed